Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Contrast agents in radiology: current agents approved, recommendations, and safety aspects].

Literature DB >> 23340684

[Contrast agents in radiology: current agents approved, recommendations, and safety aspects].

Abstract

The manuscript summarizes current approved contrast media and their indications. Contrast agents that are discussed include iodinated contrast agents, magnetic resonance (MR) contrast agents, and ultrasound contrast agents. Allergic and non-allergic renal adverse events are described. The clinical issue of metformin and the administration of contrast agents are updated. Nephrogenic systemic fibrosis (NSF) is discussed and safety issues of available MR contrast agents are analyzed. The most recent changes in European Society of Urogenital Radiology (ESUR) guidelines are also presented.

Entities: Chemical Disease

Mesh：

Substances：
Contrast Media

Year: 2013 PMID： 23340684 DOI： 10.1007/s00117-012-2429-6

Source DB: PubMed Journal: Radiologe ISSN： 0033-832X Impact factor: 0.635

14 in total

1. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008.

Authors: M Claudon; D Cosgrove; T Albrecht; L Bolondi; M Bosio; F Calliada; J-M Correas; K Darge; C Dietrich; M D'Onofrio; D H Evans; C Filice; L Greiner; K Jäger; N de Jong; E Leen; R Lencioni; D Lindsell; A Martegani; S Meairs; C Nolsøe; F Piscaglia; P Ricci; G Seidel; B Skjoldbye; L Solbiati; L Thorelius; F Tranquart; H P Weskott; T Whittingham
Journal: Ultraschall Med Date: 2008-02 Impact factor: 6.548

2. Late adverse reactions to intravascular iodine based contrast media: an update.

Authors: Marie-France Bellin; Fulvio Stacul; Judith A W Webb; Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Peter Aspelin; Olivier Clement; Gertraud Heinz-Peer; Peter Reimer; Aart van der Molen
Journal: Eur Radiol Date: 2011-07-16 Impact factor: 5.315

3. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations.

Authors: Michael Girardi; Jonathan Kay; Dirk M Elston; Philip E Leboit; Ali Abu-Alfa; Shawn E Cowper
Journal: J Am Acad Dermatol Date: 2011-07-02 Impact factor: 11.527

4. Immediate hypersensitivity reaction to gadolinium-based MR contrast media.

Authors: Jae-Woo Jung; Hye-Ryun Kang; Min-Hye Kim; Whal Lee; Kyung-Up Min; Moon-Hee Han; Sang-Heon Cho
Journal: Radiology Date: 2012-05-01 Impact factor: 11.105

5. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.

Authors: Michael V Knopp; Thomas Balzer; Marc Esser; Franciska K Kashanian; Predip Paul; Hans P Niendorf
Journal: Invest Radiol Date: 2006-06 Impact factor: 6.016

Review 6. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR).

Authors: S K Morcos; H S Thomsen; J A Webb
Journal: Eur Radiol Date: 1999 Impact factor: 5.315

7. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses.

Authors: Christopher H Hunt; Robert P Hartman; Gina K Hesley
Journal: AJR Am J Roentgenol Date: 2009-10 Impact factor: 3.959

Review 8. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

Authors: Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb
Journal: Eur Radiol Date: 2012-08-04 Impact factor: 5.315

[Contrast agents in radiology: current agents approved, recommendations, and safety aspects].

1. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008.

2. Late adverse reactions to intravascular iodine based contrast media: an update.

3. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations.

4. Immediate hypersensitivity reaction to gadolinium-based MR contrast media.

5. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.

Review 6. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR).

7. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses.

Review 8. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

9. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis.

10. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease.

1. [Indications for contrast media].

Review 2. [Optimized detection and characterization of liver metastases : The role of current MRI contrast agents].